Biofabricação de enxertos porosos de PCL/FastOs™: aplicação óssea

A Engenharia de Tecidos é um domínio multidisciplinar que combina especialistas de múltiplos domínios, no sentido de se desenvolverem substitutos biológicos para a regeneração, reparação ou restauração de funções de órgãos ou tecidos. A estratégia mais comum em engenharia de tecidos consiste na utilização de matrizes de suporte (scaffolds) tridimensionais, biocompatíveis, biodegradáveis e altamente porosos, os quais servem de substrato físico ao processo de adesão, proliferação e diferenciação celular. O objectivo deste trabalho de investigação centrou-se na produção e caracterização de scaffolds de PCL e de PCL com partículas de biovidro, abordando um processo de biofabricação, que teve por base o princípio da extrusão. Utilizou-se para tal um equipamento patenteado pelo Centro para o Desenvolvimento Rápido e Sustentado do Produto (CDRsp) designado Bioextruder. Trata-se de um sistema concebido para a produção de matrizes com ou sem encapsulamento de células, de uma forma automática, flexível e integrada. As estruturas obtidas caracterizaram-se quanto às propriedades térmicas, químicas, morfológicas e mecânicas. Realizaram-se ainda, testes de bioactividade e testes de degradação in vitro. Os resultados obtidos mostram que as condições de processamento não induzem qualquer alteração no que diz respeito às propriedades térmicas e químicas dos materiais, que o aumento do teor de biovidro conduz a uma fragmentação da matriz polimérica num período de tempo mais curto, que os scaffolds obtidos apresentam uma geometria bem definida e uma distribuição de poros uniforme. Demonstra-se assim, que a combinação da matriz polimérica (PCL) com o biovidro, sob a forma de scaffolds é promissora para aplicações em Engenharia de Tecidos e Medicina Regenerativa.

Characterization of the glial scar tissue in a murine model of spinal cord compression, with focus on hyaluronan

Spinal cord injury (SCI) is a devastating neurological disorder that affects thousands of people each year. Although in recent decades significant progress has been made in relation to understanding the molecular and cellular events underlying the nervous damage, spinal cord injury is still a highly disabling condition for which there is no curative therapy. People affected by spinal cord injuries manifested dysfunction or loss, temporary or permanent, of motor, sensory and / or autonomic functions depending on the spinal lesion damaged. Currently, the incidence rate of this type of injury is approximately 15-40 cases per million people worldwide. At the origin of these lesions are: road accidents, falls, interpersonal violence and the practice of sports. In this work we placed the hypothesis that HA is one of the component of the scar tissue formed after a compressive SCI, that it is likely synthetised by the perilesional glial cells and that it might support the permeation of the glial scar during the late phase of SCI. Nowadays, much focus is drawn on the recovery of CNS function, made impossible after SCI due to the high content of sulfated proteoglycans in the extracellular matrix. Counterbalancing the ratio between these proteoglycans and hyaluronic acid could be one of the experimental therapy to re-permeate the glial scar tissue formed after SCI, making possible axonal regrowth and functional recovery. Therefore, we established a model of spinal cord compression in mice and studied the glial scar tissue, particularly through the characterization of the expression of enzymes related to the metabolism of HA and the subsequent concentration thereof at different distances of the lesion epicenter. Our results show that the lesion induced in mice shows results similar to those produced in human lesions, in terms of histologic similarities and behavioral results. but these animals demonstrate an impressive spontaneous reorganization mechanism of the spinal cord tissue that occurs after injury and allows for partial recovery of the functions of the CNS. As regards the study of the glial scar, changes were recorded at the level of mRNA expression of enzymes metabolizing HA i.e., after injury there was a decreased expression of HA synthases 1-2 (HAS 1-2) and an increase of the expression HAS3 synthase mRNA, as well as the enzymes responsible for the HA catabolism, HYAL 1-2. But the amount of HA measured through the ELISA test was found unchanged after injury, it is not possible to explain this fact only with the change of expression of enzymes. At two weeks and in response to SCI, we found synthesized HA by reactive astrocytes and probably by others like microglial cells as it was advanced by the HA/GFAP+ and HA/IBA1+ cells co-location.